Published in Drug Week, August 1st, 2003
Two of the studied antibodies inhibited tumor cell division and exhibited other anticancer properties.
NWBT scientists were the first to discover that CXCR-4 is over-expressed in cancer. The original findings showed CXCR-4 detectable in glioblastoma and breast cancer tissue but not measurable in normal counterpart tissue. These findings formed the basis for company patent applications filed in early 1998. Subsequently, CXCR-4 has been identified...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.